Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants

• Purpose: To evaluate the impact of selenium chemoprevention (200 μg/day) on hospitalizations in HIV-positive individuals. Method: Data were obtained from 186 HIV+ men and women participating in a randomized, double-blind, placebo-controlled selenium clinical trial (1998-2000). Supplements were dispensed monthly, and clinical evaluations were conducted every 6 months. Inpatient hospitalizations, hospitalization costs, and rates of hospitalization were determined 2 years before and during the trial. Results: At enrollment, no significant differences in CD4 cell counts or viral burden were observed between the two study arms. Fewer placebo-treated participants were using antiretrovirals (p < .05). The total number of hospitalizations declined from 157 before the trial to 103 during the 2-year study. A marked decrease in total admission rates (RR = 0.38; p =.002) and percent of hospitalizations due to infection/100 patients for those receiving selenium was observed (p = .01). As a result, the cost for hospitalization decreased 58% in the selenium group, compared to a 30% decrease in the placebo group (p = .001). In the final analyses, selenium therapy continued to be a significant independent factor associated with lower risk of hospitalization (p = .001). Conclusion: Selenium supplementation appears to be a beneficial adjuvant treatment to decrease hospitalizations as well as the cost of caring for HIV-1-infected patients.

Ämnesord

NATURVETENSKAP  -- Biologi -- Immunologi (hsv//swe)

NATURAL SCIENCES  -- Biological Sciences -- Immunology (hsv//eng)

Nyckelord

HIV hospitalization

Hospitalization costs

Selenium therapy

abacavir

antiretrovirus agent

CD4 antigen

nucleoside derivative

placebo

proteinase inhibitor

RNA directed DNA polymerase inhibitor

selenium

adjuvant chemotherapy

adult

article

cell count

chemoprophylaxis

clinical trial

controlled clinical trial

controlled study

diet supplementation

dose response

double blind procedure

drug screening

drug use

female

gender

health care cost

highly active antiretroviral therapy

hospital admission

hospital cost

hospitalization

human

human cell

Human immunodeficiency virus 1

Human immunodeficiency virus infection

major clinical study

male

pilot study

priority journal

randomized controlled trial

risk assessment

time

toxicity

treatment outcome

virus load

Antiretroviral Therapy

Highly Active

CD4 Lymphocyte Count

Chemotherapy

Adjuvant

Dietary Supplements

Double-Blind Method

Florida

HIV Infections

Hospital Costs

Humans

Middle Aged

Viral Load

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)